drugset

Drugs / 111In-CP04

Follow last change Nov 2018 re-read 9 days ago

111In-CP04

also known as 111In-CP04 (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 · CP04

Developed for: medullary thyroid gland carcinoma
Investigated by: Erasmus Medical Center · INRASTES, NCSR Demokritos, Athens, Greece · Jagiellonian University · Medical University Innsbruck · NATIONAL CENTRE FOR NUCLEAR RESEARCH, Poland · Paola Anna Erba
+2 more
· University Hospital Freiburg · University Medical Centre Ljubljana

Trials 1

today NCT03246659 · Ph 1

20172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT03246659	Aug 2016 → Nov 2018	medullary thyroid gland carcinoma	Paola Anna Erba	Completed	No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	111In-CP04	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03246659 ↗
Known as	111In-CP04 (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2	“111In-CP04 (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2” NCT03246659 ↗
Known as	CP04	“radiolabelled peptide CP04” NCT03246659 ↗
Modality	Peptide	“radiolabelled peptide CP04” NCT03246659 ↗
Route	Intravenous	“i.v. administration” NCT03246659 ↗